<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cardiovascular complications are frequent in acromegalic patients </plain></SENT>
<SENT sid="1" pm="."><plain>Several studies reported increased prevalence of traditional <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> and early development of <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> and of structural vascular alterations, with subsequent increased risk of <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, <z:hpo ids='HP_0011010'>chronic</z:hpo> exposure to high levels of GH and IGF-I leads to the development of the so called "acromegalic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>", characterized by concentric biventricular <z:mpath ids='MPATH_159'>hypertrophy</z:mpath>, diastolic dysfunction and, additionally, by progressive impairment of systolic performance leading to overt <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0018824" disease_type="Disease or Syndrome" abbrv="">Cardiac valvulopathies</z:e> and <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> have also been documented and may concur to the deterioration of cardiac function </plain></SENT>
<SENT sid="4" pm="."><plain>Together with strict control of <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e>, early control of GH and IGF-I excess, by surgical or pharmacological therapy, has been reported to ameliorate cardiac and <z:mp ids='MP_0005266'>metabolic abnormalities</z:mp>, leading to a significant reduction of <z:hpo ids='HP_0001712'>left ventricular hypertrophy</z:hpo> and to a consistent improvement of cardiac performance </plain></SENT>
</text></document>